These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 37614020)

  • 1. Authors Reply to Comment on Rotshild et al's "The Risk for Prostate Cancer With Calcium Channel Blockers".
    Rotshild V; Matok I
    Ann Pharmacother; 2024 Apr; 58(4):443. PubMed ID: 37614020
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on Rotshild et al's "The Risk for Prostate Cancer With Calcium Channel Blockers".
    Liao KF; Hwang BF; Liu CS; Lai SW
    Ann Pharmacother; 2024 Apr; 58(4):441-442. PubMed ID: 37614019
    [No Abstract]   [Full Text] [Related]  

  • 3. Inverse association between prostate cancer and the use of calcium channel blockers.
    Debes JD; Roberts RO; Jacobson DJ; Girman CJ; Lieber MM; Tindall DJ; Jacobsen SJ
    Cancer Epidemiol Biomarkers Prev; 2004 Feb; 13(2):255-9. PubMed ID: 14973089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium channel blocker use and the risk of prostate cancer.
    Vezina RM; Lesko SM; Rosenberg L; Shapiro S
    Am J Hypertens; 1998 Dec; 11(12):1420-5. PubMed ID: 9880123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do calcium channel blockers appear to have a protective effect on the development of prostate cancer clinically?
    Zhang P; Hu WL; Wang XH
    Urol Oncol; 2016 May; 34(5):242-3. PubMed ID: 27036219
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to Joe O'Sullivan, Daniel Heinrich, Nicholas D. James, et al's Letter to the Editor re: The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer. Eur Urol 2019;75:e53.
    Leibowitz-Amit R
    Eur Urol; 2019 Jul; 76(1):e19. PubMed ID: 30928161
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to Alessia Cimadamore, Marina Scarpelli, Liang Cheng, et al's Letter to the Editor, re: Maria Chiara Sighinolfi, Bernardo Rocco's Words of Wisdom re: EAU Guidelines: Prostate Cancer 2019. Mottet N, van den Bergh RCN, Briers E, et al. https://uroweb.org/guideline/prostate-Cancer/. Eur Urol 2019, 76:871.
    Sighinolfi MC; Rocco B
    Eur Urol; 2020 May; 77(5):e128-e129. PubMed ID: 32067794
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to: Calcium channel blockers therapy and the risk of prostate cancer death.
    Santala EEE; Rannikko A; Murtola TJ
    Int J Cancer; 2020 Feb; 146(4):1175. PubMed ID: 31633796
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Letter to the Editor: P. van Damme et al., Vaccine 34 (2016) 757-761, as a reply to Ryser et al's letter in Vaccine.
    Van Damme P; Stanley M
    Vaccine; 2016 Aug; 34(36):4272. PubMed ID: 27452650
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of calcium channel blockers in prostate cancer: Friends or foe?
    Han QF; Ren XF; Wu L; Li T; Yao HC
    Int J Cardiol; 2016 Jan; 203():740-1. PubMed ID: 26587732
    [No Abstract]   [Full Text] [Related]  

  • 11. The Risk for Prostate Cancer With Calcium Channel Blockers: A Systematic Review, Meta-Analysis, and Meta-Regression.
    Rotshild V; Rabkin N; Matok I
    Ann Pharmacother; 2023 Jan; 57(1):16-28. PubMed ID: 35645169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcium channels and prostate cancer.
    Shapovalov G; Skryma R; Prevarskaya N
    Recent Pat Anticancer Drug Discov; 2013 Jan; 8(1):18-26. PubMed ID: 22694290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between the Overall Risk of Prostate Cancer and Use of Calcium Channel Blockers: A Systematic Review and Meta-analysis.
    Yang H; Yu Y; Hu X; Wang W; Yang X; Liu H; Ren L; Zhang X; Feng X; Liu L
    Clin Ther; 2020 Sep; 42(9):1715-1727.e2. PubMed ID: 32807506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcium channel blockers and the incidence of breast and prostate cancer: A meta-analysis.
    Thakur AA; Wang X; Garcia-Betancourt MM; Forse RA
    J Clin Pharm Ther; 2018 Aug; 43(4):519-529. PubMed ID: 29656432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short versions of the Geriatric Depression Scale (GDS) among widowed older people in Taiwan: Comparing their psychometric properties.
    Li YP; Lin CY; Hu FW; Shih SA
    Australas J Ageing; 2021 Dec; 40(4):e294-e300. PubMed ID: 33724655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No evidence for increased prostate cancer risk among calcium channel blockers user.
    Fan Y; Zhou Y; Gong D; Zou C
    Int J Cardiol; 2015 Dec; 201():255-7. PubMed ID: 26301650
    [No Abstract]   [Full Text] [Related]  

  • 17. Calcium channel blockers and prostate cancer.
    Loughlin KR
    Urol Oncol; 2014 Jul; 32(5):537-8. PubMed ID: 24814406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer risk and mortality in users of calcium channel blockers. A cohort study.
    Sørensen HT; Olsen JH; Mellemkjaer L; Marie A; Steffensen FH; McLaughlin JK; Baron JA
    Cancer; 2000 Jul; 89(1):165-70. PubMed ID: 10897013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to Magnaterra et al's unveiling hydrochlorothiazide: Skin cancer risk and hidden interactions.
    Azoulay L; St-Jean A; Platt RW
    J Am Acad Dermatol; 2023 Nov; 89(5):e247-e248. PubMed ID: 37499984
    [No Abstract]   [Full Text] [Related]  

  • 20. Do calcium channel blockers increase the risk of cancer?
    Pahor M; Guralnik JM; Salive ME; Corti MC; Carbonin P; Havlik RJ
    Am J Hypertens; 1996 Jul; 9(7):695-9. PubMed ID: 8806983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.